BTIG downgraded Alector (ALEC) to Neutral from Buy without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm says the study outcome makes it “leery” of the ongoing PROGRESS-AD trial where a similar approach is being tested to see if increased levels of extracellular protein progranulin will help patients with Alzheimer’s disease.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector downgraded to Market Perform from Outperform at William Blair
- Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
- Alector downgraded to Neutral from Outperform at Mizuho
- Alector downgraded to Hold from Buy at TD Cowen
- Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings